What Does Nektar Therapeutics’ Valuation Trend Indicate?
Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).
AstraZeneca’s Respiratory Drugs: Pulmicort, Daliresp, and Tudorza
In 3Q17, Tudorza generated revenues of $37.0 million, which reflected an ~21.0% decline on a YoY basis.
Ionis Pharmaceuticals’ Valuation Compared to Its Peers
According to March 20, 2017, data, Ionis stock has risen 4.1% over the last 12 months.
How Ionis Pharmaceuticals’ Valuation Compares to Its Peers
Ionis’s stock value has fallen 42% over the last 12 months. Analysts estimate that the stock has the potential to return ~27% over the next 12 months.